Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Therapeutics Année : 2019

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Dates et versions

hal-04526710 , version 1 (29-03-2024)

Identifiants

Citer

Sandhya Khurana, Guy Brusselle, Elisabeth Bel, J. Mark Fitzgerald, Matthew Masoli, et al.. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics, 2019, 41 (10), pp.2041-2056.e5. ⟨10.1016/j.clinthera.2019.07.007⟩. ⟨hal-04526710⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More